Skip to main content

Table 1 Distributions of concentrations of urinary metabolites of organophosphate flame retardants (ng/ml; specific gravity-corrected) in female papillary thyroid cancer cases and controls

From: A case-control study of exposure to organophosphate flame retardants and risk of thyroid cancer in women

Flame retardant

MDL

% Detected

Cases (n = 100)

Controls (n = 100)

Median

25th–75th Percentile

Median

25th–75th Percentile

BCIPP

0.185

44.5

0.242

<MDL – 0.280

<MDL

<MDL – 0.705

DPHP

0.104

97

0.802

0.457–1.549

0.843

0.506–1.450

BDCIPP

0.046

97.5

0.729

0.344–1.777

0.604

0.276–1.336

ipPPP

0.020

100

2.569

1.361–4.758

2.251

1.300–4.201

BCIPHIPP

0.001

99.5

0.160

0.084–0.377

0.214

0.093–0.564

  1. bis(1-chloro-2-propyl)1-hydroxy-2-propyl phosphate (BCIPHIPP), bis(1-chloro-2-propyl) phosphate (BCIPP), diphenyl phosphate (DPP), bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), isopropyl-phenyl phenyl phosphate (ip-PPP), and tert-butyl phenyl phenyl phosphate (tb-PPP), MDL (method detection limit)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us